The Haifa-based placenta-based cell therapy products developer has been awarded the grant by the Chief Scientist's Israel Innovation Authority.
Israeli placenta-based cell therapy products developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) unit Pluristem Ltd., has been awarded NIS 12.7 million New Israeli Shekels ($3.3 million) grant from the Ministry of Economy and Industry's Israel Innovation Authority (Previously the Office of the Chief Scientist OCS). The grant will support clinical trials and R&D activities in 2016 for the Haifa-based stem cell developer.
Pluristem chairman and CEO Zami Aberman said, "The continued backing of the Israeli Innovation Authority is a vote of confidence in Pluristem technology and strategy and supports the execution of our plans.”
Published by Globes [online], Israel business news - www.globes-online.com - on May 9, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016
Zami Aberman